Abstract
In the quest for more effective approaches to reduce the time, cost, and risks associated with development of new pharmaceuticals, High Content Analysis (HCA) is emerging as a valuable tool for in vitro predictive toxicity testing. Enabling rapid collection and analysis of information-rich cell images from thousands of samples a day, HCA offers high enough throughput for routine screening (High Content Screening, HCS) and mechanistic investigations to be performed at the early stages of discovery and preclinical development. By interrogating multiple endpoints simultaneously in the context of the same cells, candidate drugs can be grouped and prioritized according to the types and severity of cell effects they induce relative to reference compounds. At the same time, the signature drug response profiles captured by HCA provide valuable insights into mechanisms of toxicity. This chapter provides step-by-step protocols used for HCA cardiotoxicity testing of kinase inhibitors and other compounds of interest in oncology. Critical to the success of this approach is the selection and careful handling of a cell model that is amenable to high throughput HCA techniques while faithfully recapitulating human cardiomyocyte physiology in the dish with minimal batch-to-batch variability. Commercial human stem cell-derived cardiomyocytes (hSC-CM) provide a tractable and highly relevant model for this purpose. With robust quality-controlled hSC-CM cultures serving as a common test system, cardiotoxicity data obtained by HCA has the potential to be integrated with data from complementary in vitro tests—particularly those assessing electrophysiological effects—to provide more comprehensive evaluation and improved prediction of clinical responses.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Segall MD, Barber C (2014) Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discov Today. doi:10.1016/j.drudis.2014.01.006
O’Brien PJ (2014) High-content analysis in toxicology: screening substances for human toxicity potential, elucidating subcellular mechanisms and in vivo use as translation safety biomarkers. Basic Clin Pharmacol Toxicol 115:4–17. doi:10.1111/bcpt.12227
GE Healthcare Application Note 2916473AA (2016) Assessing cardiac activity with high-content analysis: quantitating dynamic calcium flux and contractility with Cytiva Plus Cardiomyocytes and IN Cell Analyzer. https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/1444842538846/litdoc29164723_20151014190842.pdf. Accessed 20 July 2016
Pointon A, Abi-Gerges N, Cross MJ, Sidaway JE (2013) Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol Sci 132(2):317–326. doi:10.1093/toxsci/kft005
Laverty HG et al (2011) How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 163(4):675–693
Redfern WS et al (2010) Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114:232 (abstract 1081)
Vishal BS et al (2016) WITHDRAWN—a resource for withdrawn and discontinued drugs. Nucleic Acids Res 44:D1080–D1086
Roquemore L (2016) Improving predictivity. Innov Pharm Technol 52:25–29
Chi KR (2013) Revolution dawning in cardiotoxicity testing. Nat Rev Drug Discov 12:565–567
ICH Expert Working Group (2005) ICH harmonized tripartite guideline: the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals S7B. Available via ICH: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf. Accessed 20 July 2016
Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7(5):332–344. doi:10.1038/nrc2106
Mellor HR, Bell AR, Valentin J-P et al (2011) Cardiotoxicity associated with targeting kinase pathways. Toxicol Sci 120(1):14–32. doi:10.1093/toxsci/kfq378
Orphanos GS, Ioannidis GN, Ardavanis AG (2009) Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 48(7):964–70
Cheng H, Force T (2010) Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 53(2):114–120
Gupta R, Maitland ML (2011) Sunitinib, hypertension and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep 13(6):430–435
Lemieux H, Hoppel CL (2009) Mitochondria in the human heart. J Bioenerg Biomembr 41:99–106
Young JD (2013) Metabolic flux rewiring in mammalian cell culture. Curr Opin Biotechnol 24(6). doi:10.1016/j.copbio.2013.04.016
Marroquin LD, Hynes J, Dykens JA et al (2007) Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97(2):153–161
Will Y, Dykens JA, Nadanaciva S et al (2008) Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 106(1):153–161
Rana P, Anson B, Engle S et al (2012) Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol Sci 130(1):117–131
Rosato RR, Almenara JA, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res 63(13):3637–3645
Kerkela R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916
Omar HR (2012) Amiodarone-induced T-U fusion. Am J Emerg Med 30(9):2081.e1-e2
ClinicalTrials.gov (2012) Safety and tolerability study of TAK-165 in subjects with tumors expressing HER-2. https://clinicaltrials.gov/ct2/show/NCT00034281?term=TAK165&rank=1. Accessed 22 July 2016
Disclaimer
GE Healthcare Cytiva: In Cell Analyzer products are for research use only and not for diagnostic or therapeutic use.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Roquemore, L., Kauss, M.A., Hather, C., Thomas, N., Uppal, H. (2017). In Vitro Cardiotoxicity Investigation Using High Content Analysis and Human Stem Cell-Derived Models. In: Clements, M., Roquemore, L. (eds) Stem Cell-Derived Models in Toxicology. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6661-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6661-5_13
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6659-2
Online ISBN: 978-1-4939-6661-5
eBook Packages: Springer Protocols